Is NCT05853367 recruiting in Hackensack, NJ?

Yes, NCT05853367 is currently recruiting participants at its Hackensack, NJ location. This metastatic solid tumors clinical trial is actively enrolling qualified participants.

How do I join the metastatic solid tumors clinical trial in Hackensack?

To join this clinical trial in Hackensack, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Hackensack clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Metastatic Solid Tumors Clinical Trial in Hackensack, NJ

About This Metastatic Solid Tumors Study in Hackensack

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

Has histologically or cytologically confirmed solid tumor by pathology report that is advanced/metastatic

Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to study enrollment

Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable (\>4 weeks) antiretroviral therapy (ART)

Arm 1: Oncogenic receptor tyrosine kinase (RTK) pathway alterations confirmed by a historical report or local testing (tissue or blood) and have received, or been intolerant to, all available treatment known to confer clinical benefit

Arm 2: Tumor types known to be sensitive to anti-programmed cell death 1 protein (PD-1)/ligand 1 (L1) therapies are eligible. Tumor types permitted include: melanoma, non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/ROS1 mutations, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, MSI-high CRC, endometrial cancer, cervical cancer, small cell lung cancer, triple negative breast cancer, esophageal cancer, gastric cancer, biliary tract cancer, hepatocellular carcinoma, head and neck squamous cancer, cutaneous squamous cancer, anal squamous cancer, and mesothelioma

Arm 3: Has histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

Has not recovered to common terminology criteria for adverse events (CTCAE) Grade 1 or better from any adverse events that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study

Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years

History of hyperparathyroidism or hypercalcemia

Has one or more of the following ophthalmological findings/conditions: a) Intraocular pressure \>21 mm Hg and/or any diagnosis of glaucoma b) Diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and c) Diagnosis of retinal degenerative disease

Has clinically significant cardiovascular disease

Bullous exfoliative skin disorders of any grade

Known hypersensitivity to MK-0472, MK-1084, or pembrolizumab, or any of their excipients

Received therapy with a proton-pump inhibitor or an H2 histamine blocker receptor antagonist within 7 days before the first scheduled day of study dosing

Has discontinued prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor due to an adverse event

Received prior systemic anticancer therapy including investigational agents within 4 weeks before first dose

Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration

Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication

Has known additional malignancy that is progressing or has required active treatment within the past 2 years

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention

Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy

Has history of pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Has active infection requiring systemic therapy

Has history of allogeneic tissue/solid organ transplant

Have not adequately recovered from major surgery or have ongoing surgical complications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Hackensack?

Yes, this clinical trial (NCT05853367) has an active research site in Hackensack, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Solid Tumors Treatment Options in Hackensack, NJ

If you're searching for metastatic solid tumors treatment options in Hackensack, NJ, this clinical trial (NCT05853367) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Hackensack research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

Metastatic Solid Tumors Clinical Trial in Hackensack, NJ

Expert Care in Hackensack

IRB Approved

No-Cost Care

Apply for This Hackensack Location

Why Participate?

Simple Process